Activities Report and Sales Note to Accompany Appendix 4C
Melbourne (Australia) – 27th July 2020. Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th June 2020 and a Q2 2020 sales update
Telix Pharmaceuticals Limited is pleased to provide its Activities Report and Appendix 4C for the quarter ending 30th June 2020 and a Q2 2020 sales update for its prostate cancer imaging product, the TLX591-CDx kit (Kit for the preparation of 68Ga-PSMA-11 Injection).
To read full media release please click here.
First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey
Melbourne (Australia) and Istanbul (Turkey) – 22nd October 2020. Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that...
Telix Pharmaceuticals to Participate at AusBiotech + Invest 2020
12th October 2020 – Corporate Spotlight | Telix Pharmaceuticals will participate in AusBiotech + Invest 2020
Telix to Present at European Association of Nuclear Medicine 2020 Annual Congress
12th October 2020 – Clinical Spotlight | Telix to Present at European Association of Nuclear Medicine 2020 Virtual Conference
Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent
Melbourne (Australia) – 6th October 2020. Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
Melbourne (Australia) and Indianapolis (U.S.A.) – 24th September 2020. Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for...
First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic
Melbourne and Adelaide (Australia) – 21st September 2020. Telix announces first two patients dosed in phase I trial of lung...
Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...
Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging
Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...
FDA Grants Orphan Drug Designation for TLX102
Melbourne (Australia) – 31st August 2020. Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of...
Half Year Shareholder Update
Melbourne (Australia) – 21st August 2020. Telix Pharmaceuticals Limited Announces Half-year Shareholder Update
First patient dosed in renal cancer imaging study in Japan
Melbourne (Australia) – 18th August 2020. Telix announces the first patient has been dosed in a Phase I/II study of...
Drug Master File for Glioblastoma Therapy Product Filed with FDA
Melbourne (Australia) and Indianapolis, IN (USA) – 11th August 2020. Telix announces it has submitted a Drug Master File to...
Completion of Phase I Enrolment of Japanese Renal Cancer Study
Tokyo (Japan) – 27th October 2020. Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment...